Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know

Mean analyst price target for Relmada Therapeutics (RLMD) implies a 92.2% upside. Although the price-target mean is not always reliable, broad analyst agreement in raising earnings estimates suggests upside potential for the stock; treat as a cautiously optimistic signal likely to produce modest near-term stock movement rather than a definitive catalyst.

Analysis

Mean analyst price target for Relmada Therapeutics (RLMD) implies a 92.2% upside. Although the price-target mean is not always reliable, broad analyst agreement in raising earnings estimates suggests upside potential for the stock; treat as a cautiously optimistic signal likely to produce modest near-term stock movement rather than a definitive catalyst.